Table 2 The correlation between SII and clinicopathologic characteristics in training and validation cohorts
From: Systemic immune-inflammation index predicts prognosis of patients with advanced pancreatic cancer
Variables | Training (N = 197) | Validation (N = 222) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
SII ≤ 440 | % | SII > 440 | % | P | SII ≤ 440 | % | SII > 440 | % | P | |
Age (years) | ||||||||||
 ≤ 60 | 39 | 42.9 | 56 | 52.8 | 0.198 | 41 | 46.1 | 64 | 48.1 | 0.785 |
 > 60 | 52 | 57.1 | 50 | 47.2 |  | 48 | 53.9 | 69 | 51.9 |  |
Sex | ||||||||||
 Male | 55 | 60.4 | 67 | 63.2 | 0.769 | 62 | 69.7 | 85 | 63.9 | 0.389 |
 Female | 36 | 39.6 | 39 | 36.8 |  | 27 | 30.3 | 48 | 36.1 |  |
Location | ||||||||||
 Head | 34 | 37.4 | 53 | 50 | 0.085 | 38 | 42.7 | 52 | 39.1 | 0.676 |
 Body/tail | 57 | 62.6 | 53 | 50 |  | 51 | 57.3 | 81 | 60.9 |  |
Metastasis | ||||||||||
 No | 26 | 28.6 | 15 | 14.2 | 0.014 | 19 | 21.3 | 23 | 17.3 | 0.487 |
 Yes | 65 | 71.4 | 91 | 85.8 |  | 70 | 78.7 | 110 | 82.7 |  |
CA19-9 (U/mL) | ||||||||||
 ≤ 37 | 22 | 50.0 | 22 | 50.0 | 0.609 | 22 | 42.3 | 30 | 57.7 | 0.748 |
 > 37 | 69 | 45.1 | 84 | 54.9 |  | 67 | 39.4 | 103 | 60.6 |  |
TBIL (μmol/L) | ||||||||||
 ≤ 17 | 80 | 87.9 | 82 | 77.4 | 0.062 | 77 | 86.5 | 107 | 80.5 | 0.278 |
 > 17 | 11 | 12.1 | 24 | 22.6 |  | 12 | 13.5 | 26 | 19.5 |  |
ALB (g/L) | ||||||||||
 ≤ 35 | 2 | 2.2 | 11 | 10.4 | 0.023 | 5 | 5.6 | 8 | 6.0 | 1.000 |
 > 35 | 89 | 97.8 | 95 | 89.6 |  | 84 | 94.4 | 125 | 94.0 |  |
ALP (U/L) | ||||||||||
 ≤ 125 | 70 | 76.9 | 69 | 65.1 | 0.085 | 71 | 79.8 | 86 | 64.7 | 0.016 |
 > 125 | 21 | 23.1 | 37 | 34.9 |  | 18 | 20.2 | 47 | 35.3 |  |
ALT (U/L) | ||||||||||
 ≤ 35 | 69 | 75.8 | 79 | 74.5 | 0.870 | 72 | 80.9 | 100 | 75.2 | 0.332 |
 > 35 | 22 | 24.2 | 27 | 25.5 |  | 17 | 19.1 | 33 | 24.8 |  |
AST (U/L) | ||||||||||
 ≤ 40 | 76 | 83.5 | 89 | 84.0 | 1.000 | 80 | 89.9 | 106 | 79.7 | 0.062 |
 > 40 | 15 | 16.5 | 17 | 16.0 |  | 9 | 10.1 | 27 | 20.3 |  |